%PDF-1.4
%
51 0 obj
<>
endobj
48 0 obj
<>
endobj
116 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-05-11T17:28:02Z
2024-03-29T07:13:05-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-29T07:13:05-07:00
application/pdf
Heather
2003-403.june
uuid:333595cf-1dd2-11b2-0a00-3e0927bd3700
uuid:333595d1-1dd2-11b2-0a00-5b0000000000
endstream
endobj
37 0 obj
<>
endobj
38 0 obj
<>
endobj
52 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 25 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 27 0 R/Type/Page>>
endobj
14 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 29 0 R/Type/Page>>
endobj
22 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 31 0 R/Type/Page>>
endobj
130 0 obj
[134 0 R]
endobj
131 0 obj
<>stream
q
0 0 612 792 re
W n
BT
0.85091 0.85091 0.85091 rg
/T1_0 19 Tf
0.6303 0.7762 -0.7762 0.6303 16.7778 46.0632 Tm
(Personal non-commercial use only. The Journal of Rheumatology. Copyright\
\251 2004. All rights reserved)Tj
ET
Q
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
-0.00011 Tc -0.0071 Tw 10 0 0 10 54 713.1616 Tm
(lapping with dermatomyositis. CDI was diagnosed based on)Tj
-0.00459 Tw 0 -1.2 TD
(the results of 5% NaCl loading test and presence of nocturia)Tj
0.36571 Tw T*
(without psychogenic polydipsia. It was not likely that)Tj
0.2471 Tw T*
(pulsed steroid therapy caused CDI by thrombosis, since)Tj
0.2623 Tw T*
[(anterior pituitary function was normal. Interestingly)64.8 (, the)]TJ
0.127 Tw T*
[(disappearance of )54.8 (A)128.9 (VPcAb and restoration of normal post-)]TJ
0.02409 Tw T*
[(pituitary function after IV)-256.4 (CYC and steroid therapy suggest)]TJ
0.0631 Tw T*
(that induction of remission of autoimmune CDI is possible)Tj
0.0397 Tw T*
[(when a residual amount of )54.8 (A)128.9 (V)0.1 (P)-253 (granules are still present at)]TJ
0.02499 Tw T*
(the onset of the disease.)Tj
0.3134 Tw 1.2 -1.2 Td
[(Another important observation is that )54.8 (A)128.9 (VPcAb were)]TJ
-0.0271 Tw -1.2 -1.2 Td
(found \(titer 1:8\) in one of 6 patients with active SLE without)Tj
-0.0157 Tw T*
(CDI, but in none of the patients with inactive SLE nor in the)Tj
0.0417 Tw T*
[(normal controls. It has been recently reported that )54.9 (A)128.9 (VPcAb)]TJ
0.0565 Tw T*
(could be a good marker for CDI in patients with endocrine)Tj
0.05389 Tw T*
(autoimmune diseases without CDI)Tj
-0.0567 Tc 0 Tw 6.5 0 0 6.5 193.6408 536.4616 Tm
(11)Tj
-0.00011 Tc 0.05389 Tw 10 0 0 10 199.7721 533.1616 Tm
[(; in particular)39.7 (, during 5)]TJ
0.03529 Tw -14.5772 -1.2 Td
[(years of followup, 4 )54.9 (A)128.9 (VPcAb-positive patients with normal)]TJ
0.1774 Tw T*
(posterior pituitary function developed partial or complete)Tj
0.0769 Tw T*
[(CDI. Our results suggest that )54.8 (A)128.9 (VPcAb can be detected not)]TJ
0.04089 Tw T*
(only in patients with active SLE and CDI, but also in those)Tj
0.166 Tw T*
[(without CDI. Since )54.8 (A)128.9 (VPcAb-positive patients with active)]TJ
-0.01711 Tw T*
(SLE are usually treated with aggressive immunosuppressive)Tj
0.0612 Tw T*
[(therapy)64.8 (, the possible development of clinical CDI could be)]TJ
0.1125 Tw T*
(avoided by the treatment interrupting autoimmune mecha-)Tj
0.02499 Tw T*
(nisms leading to the clinical disease.)Tj
/T1_2 1 Tf
0 Tw 0 -2.4 TD
(REFERENCES)Tj
/T1_1 1 Tf
0.02499 Tw 8 0 0 8 61 391.1616 Tm
[(1.)-875.1 (Arafah BM, Nasrallah MP)110.7 (. Pituitary tumors: pathophysiology)64.8 (, )]TJ
1.675 -1.25 Td
(clinical manifestations and management. Endocr Relat Cancer)Tj
0 Tc 0 Tw 0 -1.25 TD
(2001;8:287-305. )Tj
-0.00011 Tc 0.02499 Tw 31.325 42.921 Td
[(2.)-875.1 (Hensen J, Seuf)17.7 (ferlein )17.7 (T)74 (, Oelkers )17.7 (W)91.8 (.)-0.1 ( )54.8 (Atherosclerosis, aortic stenosis)]TJ
1.675 -1.25 Td
(and sudden onset central diabetes insipidus. Exp Clin Endocrinol)Tj
T*
(Diabetes 1997;105:227-33.)Tj
-1.675 -1.25 Td
[(3.)-875.1 (Schucart )17.7 (W)110.9 (A, Jackson I. Management of diabetes insipidus in)]TJ
1.675 -1.25 Td
[(neurosur)17.7 (gical patients. J Neurosur)17.7 (g 1976;44:65-7.)]TJ
-1.675 -1.25 Td
[(4.)-875.1 (Y)110.8 (uan XQ, )17.7 (W)79.9 (ade CE. Neuroendocrine abnormalities in patients with)]TJ
1.675 -1.25 Td
[(traumatic brain injury)64.8 (. Front Neuroendocrinol 1991;12:209-30.)]TJ
-1.675 -1.25 Td
[(5.)-875.1 (Imai H, Okuyama S, Komatsuda )54.8 (A, )17.7 (W)79.9 (akui H, Miura )54.8 (AB. Central)]TJ
1.675 -1.25 Td
(diabetes insipidus due to lymphocytic )Tj
T*
[(infundibuloneurohypophysitis. )54.9 (Am J Med 2000;109:497-9.)]TJ
-1.675 -1.25 Td
[(6.)-875.1 (De Bellis )54.8 (A, Colao )54.8 (A, Bizzarro )54.8 (A, et al. Longitudinal study of )]TJ
1.675 -1.25 Td
(vasopressin-cell antibodies and of hypothalamic-pituitary region on)Tj
T*
(magnetic resonance imaging in patients with autoimmune and )Tj
T*
(idiopathic complete central diabetes insipidus. J Clin Endocrinol)Tj
T*
(Metab 2002;87:3825-9. )Tj
-1.675 -1.25 Td
[(7.)-875.1 (Scherbaum )17.7 (W)110.9 (A, Bottazzo GF)79.7 (. )54.8 (Autoantibodies to vasopressin cells)]TJ
1.675 -1.25 Td
(in idiopathic diabetes insipidus: evidence for an autoimmune)Tj
T*
(variant. Lancet 1983;1:897-901.)Tj
-1.675 -1.25 Td
[(8.)-875.1 (De Bellis )54.8 (A, Bizzarro )54.8 (A, )54.8 (Amoresano Paglionico )17.7 (V)128.9 (, et al. Detection)]TJ
1.675 -1.25 Td
(of vasopressin cell antibodies in some patients with autoimmune)Tj
T*
(endocrine diseases without overt diabetes insipidus. Clin)Tj
T*
(Endocrinol \(Oxf\) 1994;40:173-7.)Tj
-1.675 -1.25 Td
[(9.)-875.1 (T)69.9 (ekin N, Kural N, Kocak )54.8 (AK, Kose S. Diabetes insipidus in a )]TJ
1.675 -1.25 Td
[(pediatric patient with systemic lupus erythematosus. )54.8 (A)-220.1 (case report.)]TJ
T*
[(T)35 (urk J Pediatr 1997;39:281-4.)]TJ
-2.175 -1.25 Td
[(10.)-875.1 (Sanchez-Roman J, Castillo-Palma MJ, Ocana Medina C, )]TJ
2.175 -1.25 Td
[(V)59.8 (illamil-Fernandez F)79.7 (,)-0.1 ( )17.7 (W)39.8 (ichmann I. Neurogenic diabetes insipidus)]TJ
T*
[(in patients with systemic lupus erythematosus. )54.8 (Ann Rheum Dis)]TJ
0 Tc 0 Tw T*
(1998;57:261-2. )Tj
-0.00011 Tc 0.02499 Tw -2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (De Bellis )54.8 (A, Colao )54.8 (A, Di Salle F)79.7 (, et al. )54.8 (A)-220.1 (longitudinal study of)]TJ
2.1381 -1.25 Td
(vasopressin cell antibodies, posterior pituitary function, and)Tj
T*
(magnetic resonance imaging evaluations in subclinical autoimmune)Tj
T*
(central diabetes insipidus. J Clin Endocrinol Metab )Tj
0 Tc 0 Tw T*
(1999;84:3047-51.)Tj
ET
0 0 0 1 K
54 54 m
558 54 l
S
BT
/T1_3 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 54.5 35.9844 Tm
[(Kajiyama, et al: V)110.7 (asopr)36.8 (essin antibodies in SLE)]TJ
0 Tc 0 Tw 60.9375 -0.0313 Td
(1221)Tj
ET
0 0 0 0 k
/GS0 gs
109.22 59.08 396.48 -10.83 re
f*
0.5 w
109.22 59.08 396.48 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_4 8 Tf
119.868 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology. Copyri\
ght \251 2004. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_5 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
31 0 obj
<>stream
8;Z\7#n@%\#iu"-j?$(;/h==ph)%inAD:Cb3"4_rfP(0t@#NFmq=FNr>-8*#;q`"J
)Ra%$nlqPD^=WqmM"ZgS-mKda*\!5e2g5Xaq!(Gha15XNQup(a$,P2Y'1Ws6JrJ$M
"Mb.jP>%tDI<9][Ae"O6RI=[5IQj&,1j'2=C`sESMX%>cpZ/9QW>t?KA!\%[>F?BB
_JH?q5TFWe_,:G.k0Z;@X["P"Op;t''Z+Q+Nrlif.)T(X$"!*bfi,=]-I,E6iUX
endstream
endobj
35 0 obj
[/Indexed/DeviceRGB 255 34 0 R]
endobj
34 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
107 0 obj
<>
endobj
59 0 obj
<>
endobj
63 0 obj
<>
endobj
55 0 obj
<>
endobj
98 0 obj
<>
endobj
121 0 obj
<>
endobj
54 0 obj
<>
endobj
93 0 obj
<>stream
H{PSwro.6F!\QskQ-jEAEDDyXD" IG !yIxĈ E|,ZłZ|c؇k-3Nq]oo}|Ιs~8fm8n17P"SDKWs7
[q3ng||ߚ
$MшQPy1 m9Wa$Mnn]TIX;'#vᲥ{ceG,RnVb];J KP]Y#>$\<'f%r6U$EDIql'+-SĬ7;z,H$Z$}[?6
0'Ib$ [57Hl%03noƏZ-RZw!?d?j-5Ў?]g3&9*&o?e⎉/Q1yWU22 SSSF㜦:;=`@"t?slCG~.,0M̉4+)4yZFKe
oGO-gPHl0~wLfYiɔJA2Ռ߃/2 [9$"Ç^mݒk5k?{
lz)Lߵ3.Ǡ61$?\-OX֜5т5oDpS-](&yE55=YLbGs-UdE+D܁8fLFMu
gE;,Agjn&DdQEJE[˒ƀ>[MȈ: 4Cp]8>&'Spx^ޡdV5^4K-yk푤G$fǪ$&yyN]YǽavG]o^4
{sU'⒵;76k.9?"W_?~[ns`FEKH*O,
h-y:
kt|I8 %dpWqOpWQtK`"YAR+7ɚ$EMNcmZX(/`5 hzO!1sӎ7gD339K]^ZΧO@-j[>
N}A0rğKzB6*
O.[TPq|D"*Оz@tL_J4X5UkװbJa/7Ƀ՛}יf_}|ƥ>Uk٘гdchaw?}`f^S>~RS9mf6o~:e6h;s.a-P!gg{A-BP
3WW`O?vqRd<yC͡'GS fGBhHLez/=P*gKwv
u@=ap0c|@a0b$oO@߅
WĠclggqgFHZd_#/Dfh3RT=EnK3Ų])Ofq#ɜDFQo~}ZƖB aT>bX'0@|:5|MsɩVzpXN1zsUY]a{QCANۛU^Yis$LWu)ve˒]AVh.kЧcnL1{ui;K+UŞOS>D6Ahz{@xZBmKW*5ŵV}'v=lYpC`uޭ@0RO-8w0_<7́E5n363Mu+hqY>@|[Uءoǻ:]GxTeSJ4AIyywH4R!Th,4Mn^BWmi ĮQsC@>b"As|K_W`%_RD%܂ӪgHS"'asEȰq2)'E/f
qa ʂnfZhn7v<
Iz4)Gޠi=
8 dGJqsB} /h%Ri T_*v dw8(;
8DddkX+0mod0]q"B3Vy*.X@ #!#_q>o;>FtK [(96;E-=DDj,n#5̠~w79 Ut]M]`;`M?Xr),oDpڑֽa`eq;N2,+=5?GVIpcyvk'RӘոUݧKhӜFz$ye0J|ƺ4e.xN"#ʬr|rf
wKϊ~-\@9b:ɟm*`Fs$DJ!cJ1OTqUA;64n9Mҍ!AgbW4טLY,V4WҒvT
۞=l37O}?x\|+̓(F'˜YJmQp
YSޢSN ŲuTq#ifi/_}
S
wE vCctן40q=ʽo:R5uAv~XZsJ8ӮRF'&_":w|v
ݢ9H##}zAEo_%H?(銧6Z_@^7 ̠XsԜp71\'Gn3D ҙJO=S< !lDrJ]WLonOhsT
$eO@("_\/*.R)U<\,[Ei>gKe8'lxlXxFtmِyP&k LXJ-Ɋs*[GdDT;l&geI 0q@I-jpa+9{9Lg] ?c40> DIR'(%Z^.sꝵ=->Yyu/Fo*Gi>?BYe46RՖ2O